Skip to main navigation Skip to search Skip to main content

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

  • Irene M. Ghobrial
  • , Robert Allyn Redd
  • , Jeffrey Matous
  • , Philippe Armand
  • , Erica N Boswell
  • , Stacey Chuma
  • , Kimberly Noonan
  • , Megan H. MacNabb
  • , Ranjit Banwait
  • , Courtney Hanlon
  • , Houry Leblebjian
  • , Diane Warren
  • , Jorge J. Castillo
  • , Jacob P. Laubach
  • , Claudia E. Paba-Prada
  • , Kenneth C. Anderson
  • , Paul G. Richardson
  • , Edie A. Weller
  • , Steven P Treon
  • Harvard University
  • Rocky Mountain Cancer Center, Denver, CO

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume124
Issue number21
DOIs
StatePublished - Dec 6 2014
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Oncology
  • Internal Medicine

Cite this